Hello everyone, I'm opening a new thread on this because it is...

Hello everyone, I'm opening a new thread on this because it is more of a general question and not related to the performance of SRX as a company. But there are some smarter people out there than me who might be able to shed some light.

Everyone right now is very focussed on some potential good news coming out of SRX which could lead to a step-change in usage of SIR-Spheres, and forward revenue to SRX. We have also just been reminded of another trial - SARAH - which will lead to similar anticipation at the end of 2016. All good news. Others will follow.

But I was wondering if there could also be a step-change in the other direction if a rival product concluded a trial which showed even better clinical results than SIR-Spheres? You would rationally expect that there would be a leap frogging effect, of the best product at any one time being the Gold Standard treatment - if there were multiple products available and/or new & improved products being developed.

Hence my general question to all the knowledgeable people out there - are there any rival products out there with known clinical trials which could cause a negative impact to SRX? If so do we know the details of the trials, release dates and possible impact?